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Abstract
Background: Few studies have monitored late presentation (LP) of HIV infection over the European continent, including
Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality.
Methods and Findings: LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as
HIV diagnosis with a CD4 count ,350/mm3 or an AIDS diagnosis within 6 months of HIV diagnosis among persons
presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated
with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries
contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries
(57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted
odds ratio [aOR] 0.96; 95% CI 0.95–0.97). LP decreased over time in both Central and Northern Europe among homosexual
men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users
(IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003
person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of
AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19–20.70) and over a 6-fold increased
rate in Eastern Europe (aIRR 6.64; 95% CI 3.55–12.43).
Conclusions: LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure
groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was
associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation
across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care
strategies are required to further reduce the incidence of LP.
Please see later in the article for the Editors’ Summary.
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Introduction
Approximately 40%–60% of HIV-positive persons in developed
countries continue to be diagnosed with HIV at a late stage of
infection [1]. According to the latest consensus definition from the
HIV in Europe study group, late presenters are defined as persons
presenting to a clinic that can prescribe antiretroviral therapy
(ART) with a CD4 count of less than 350/mm3 or an AIDS
defining illness [2], the current World Health Organization’s
recommended threshold for initiation of ART [3]. Late presen-
tation, which may reflect late diagnosis and/or late entry into care,
has consequences both for the individual, in terms of poorer
outcomes [4–6], and for society in terms of the risk of onward
transmission due to uncontrolled viremia and lack of awareness of
HIV serostatus [7,8]. Late presentation also has an economic
impact, with higher resource use, particularly in the first few
months following presentation [9,10]. Barriers to testing from the
patients perspective include concerns about the impact of a
positive result, fears around discrimination, confidentiality, crim-
inalisation of risk behaviours, and limited knowledge about
accessing testing or treatment on testing positive [11]. Reported
concerns by clinicians include language barriers, the belief that
lengthy counselling is required, worry about informing individuals
of a HIV-positive test result, and lack of knowledge about HIV
and potential risk behaviours [12].
Many studies have presented data on late presentation, generally
focusing on a specific country or region within a country and
applying various definitions for late presentation. Data from Eastern
Europe is particularly scarce and hence a Europe-wide perspective
of late presentation using uniform definitions can help inform policy
and decision making on future continent-wide HIV testing
strategies. Such results will provide a platform for future monitoring
of late presentation following appropriate interventions.
The Collaboration of Observational HIV Epidemiological
Research Europe (COHERE) study provides a unique opportunity
to describe the epidemiology of those testing HIV positive at a late
stage of HIV infection compared to those testing earlier, and to
look at regional differences within HIV exposure groups. The aims
of the present analyses were to describe trends in late presentation
over time in different regions of Europe and according to HIV
exposure group, and to investigate the clinical consequences of late
presentation.
Methods
Patients
COHERE is a collaboration of 33 cohorts from across Europe
and is part of the EuroCoord network (www.EuroCoord.net).
COHERE was established in 2005 with the aim of conducting
epidemiological research on the prognosis and outcome of HIV-
positive persons, which the individual contributing cohorts cannot
address themselves because of sample size or heterogeneity of
specific subgroups of HIV-positive persons. Local ethical commit-
tee and/or other regulatory approval were obtained as applicable
according to local and/or national regulations in all participating
cohorts unless no such requirement applied to observational
studies according to national regulations. Each cohort submits
data using the standardized HIV Collaboration Data Exchange
Protocol (HICDEP) [13], including information on patient
demographics, use of cART, CD4 counts, AIDS, and deaths.
Further details can be found at http://www.eurocoord.net/
partners/founding_networks/cohere.aspx.
Twenty three cohorts across 35 European countries provided
data for the present analysis. All persons aged $16 y, who
presented for care (earliest of HIV diagnosis, first clinic visit, or
enrolment into the participating cohort) for the first time after 1
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January 2000 until 1 January 2011 were included. Baseline was
defined as the date of first HIV diagnosis, or the earliest of first
clinic visit or cohort enrolment if date of HIV diagnosis was
missing, referred to as date of HIV diagnosis. Persons were
excluded if gender or HIV diagnosis was missing, if aged ,16 y,
or where there was evidence of an earlier HIV diagnosis (CD4
count, AIDS diagnosis, or starting ART) more than 1 mo prior to
first clinic visit, as were persons from Argentinean centres in
EuroSIDA and persons from the seroconverter cohorts in
COHERE, because by definition, such persons are not presenting
late.
Late presentation was defined as a person diagnosed with HIV
with a CD4 count below 350/mm3 or an AIDS defining event
regardless of the CD4 count, in the 6 mo following HIV diagnosis.
Late presentation with advanced disease was defined as a person
diagnosed with HIV with a CD4 count below 200/mm3or an
AIDS defining event, regardless of CD4 cell count, in the 6 mo
following HIV diagnosis [2]. Delayed entry into care was defined
as $3 mo between HIV diagnosis and first clinic visit, in those
where both dates were recorded. All persons were required to have
at least one CD4 count measured in the 6 mo following diagnosis.
Statistical Methods
Baseline characteristics of late presenters were compared to
non-late presenters and logistic regression was used to identify
factors associated with late presentation and late presentation with
advanced disease. Factors investigated were age, HIV-exposure
group (males having sex with males [MSM], heterosexual male,
heterosexual female, male intravenous drug user [IDU], female
IDU, other [including patients with unknown HIV exposure
group, likely to include a number of IDUs, MSMs, and
heterosexuals]), region of origin (Europe, Africa, other [including
patients from Central/Southern America and Asia], unknown),
European region of HIV diagnosis (based on the cohort location
and defined as: South: Greece, Israel, Italy, Portugal, and Spain;
Central: Austria, Belgium, France, Germany, Luxemburg, and
Switzerland; North: Denmark, Finland, Ireland, Netherlands,
Norway, Sweden, and UK; East: Belarus, Bosnia and Herzego-
vina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary,
Latvia, Lithuania, Poland, Romania, Russia, Serbia, Slovakia,
Slovenia, and Ukraine), calendar year of diagnosis, and delayed
entry into care. A priori, we were interested in comparing changes
over time within European regions and HIV exposure groups, and
performed formal tests of interaction before presenting the
stratified analyses. Logistic regression was also used to identify
characteristics associated with delayed entry into care among late
presenters.
Kaplan Meier survival analysis was used to estimate the
probability of the composite endpoint of a new AIDS defining
event/deaths and Poisson regression models to evaluate the
incidence of AIDS/death. Models were adjusted for the same
factors as above, and additionally the effect of time after HIV
diagnosis (,1, 1–2, .2 y). Recurrent AIDS events were not
collected by all participating cohorts and thus were not included.
Different sensitivity analyses were performed to assess the
robustness of our findings. Analyses were repeated excluding
persons where date of HIV infection was not available in the
dataset and excluding persons with known delayed entry into care.
We also assessed how the proportion of late presenters changed by
using a different time window around the CD4 count at HIV
diagnosis (1 mo, 12 mo) and also assuming those without a CD4
count measured were late presenters or not.
All analyses were performed using Statistical Analysis Software
Version 9.3 (Statistical Analysis Software).
Results
Of 107,735 persons in COHERE diagnosed with HIV after 1
January 2000, 84,524 were included in these analyses (78.5%;
Table S1). Persons were primarily excluded because they lacked
information on CD4 count at HIV diagnosis. Excluded persons
were more likely to be from ‘‘other’’ HIV exposure groups (i.e., not
categorised as MSM, IDU, or heterosexual), from Eastern Europe,
younger, to have no prior AIDS diagnosis at diagnosis, diagnosed
in earlier calendar years, and less likely to die. Characteristics of
the 84,524 included persons are shown in Table 1; 45,488 persons
were classified as late presenters (53.8%) and 28,081 (33.2%) as
late presenters with advanced disease. The highest proportion of
late presenters was among heterosexual males (66.1%; 11,158/
16,875), persons from clinics in Southern Europe (57.0%; 4,447/
7,796), and persons originating from Africa (65.1%; 7,708/
11,833). 11,903 of the late presenters had AIDS at HIV-1
diagnosis (20.6%), the most common diagnoses were Pneumocystis
jiroveci pneumonia (20.6%; 2,457/11,903), cytomegalovirus (ex-
cluding retinitis, 13.9%; 1,657/11,903), and oesophageal candidi-
asis (12.3%; 1,463/11,903). Among the 34,561 persons with data
on both date of HIV diagnosis and first contact with a clinic, 7.9%
(2,720/34,561) had delayed entry into care. Among late present-
ers, 7.4% had delayed entry into care (1,408/18,933); such
individuals were younger (adjusted odds ratio (aOR 0.87/10 y
older; 95% CI 0.83–0.91), presented later (aOR 0.96/year later;
95% CI 0.94–0.97), and were more likely to be under care in
Southern Europe compared to Northern Europe (aOR 2.02; 95%
CI 1.77–2.30). HIV exposure group or region of origin were not
associated with delayed entry into care among late presenters.
Late presentation declined from 57.3% (4,222/7,367) in 2000 to
51.7% (1,665/3,223) in 2010/2011 (Figure 1). The median CD4
count at diagnosis among all persons increased from 306/mm3 in
2000 to 363/mm3 in 2009. Factors associated with late
presentation included older age (aOR 1.41/10 y older; 95% CI
1.39–1.43), and region of origin, with persons from Africa (aOR
1.75; 95% CI 1.66–1.84) and persons from other regions (aOR
1.40; 95% CI 1.32–1.48) having higher odds of late presentation
compared to persons originating from Europe. Compared to
persons from Central Europe, persons under care in Southern
Europe (aOR 1.41; 95% CI 1.33–1.48) had higher odds of late
presentation, as did all HIV-exposure groups compared to MSM.
This ranged from over a doubling in heterosexual men (aOR 2.05;
95% CI 1.97–2.14) to 31% for female IDUs (aOR 1.31; 95% CI
1.18–1.46). Delayed entry into care was associated with decreased
odds of late presentation (aOR 0.91; 95% CI 0.84–0.99). After
adjustment for these confounders, there was a 4% decrease in the
odds of late presentation per later calendar year (aOR 0.96; 95%
CI 0.96–0.97). Results were similar for late presentation with
advanced disease (Figure 1), with a decrease in advanced disease at
presentation of 5% per year after adjustment (aOR 0.95; 95% CI
0.94–0.95). Results were highly consistent excluding patients with
unknown or delayed entry into care (Table S2).
Figure 2 shows the crude percentage of late presenters within
HIV-exposure groups, region, and calendar period, and the aOR
of late presentation per year of later HIV diagnosis (also shown in
Table S3). Later calendar year was associated with a decrease in
late presentation among MSM, and male and female heterosex-
uals in both Central and Northern Europe (Figure 2B and 2C). For
example, the proportion of MSMs with late presentation in
Central Europe declined from 51.9% (1,201/2,312) in 2000/2001
to 40.4% (1,352/3,348)$2008 (aOR 0.93 per year later; 95% CI
0.92–0.94) and from 48.1% (919/1,911) to 38.6% (1,731/4,484) in
Northern Europe (Figure 2C; aOR 0.95 per year later; 95% CI
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0.94–0.96). Late presentation also decreased over time in
heterosexual females from Eastern Europe from 55.6% (25/45)
in 2000/2001 to 33.9% (20/59)$2008 (aOR 0.89 per year later;
95% CI 0.80–0.98). Late presentation increased in male IDUs
from Southern Europe (Figure 2A; aOR 1.06 per year later; 95%
CI 0.99–1.13), and also among male and female IDUs from
Eastern Europe, although the aORs failed to reach statistical
significance, possibly owing to the smaller number of patients from
Eastern Europe.
Results for presentation with advanced disease are summarised
in Table 2. Within Southern Europe, late presentation with
advanced disease decreased in MSMs from 36.5% (107/293)
during 2000/2001 to 29.7% (364/1,226)$2008 (aOR 0.94 per
year later; 95% CI 0.92–0.97), but was stable in other infection
groups. In Central Europe late presentation with advanced disease
was decreasing in all HIV-exposure groups except male IDUs, and
most rapidly in MSMs, from 33.0% (763/2,312) to 20.7% (693/
3,348; aOR 0.91 per year later; 95% CI 0.90–0.92). Similar results
were seen in Northern Europe, with a decrease over time in all
HIV-exposure groups except male and female IDUs. There were
no significant changes over time in Eastern Europe in the odds of
late presentation with advanced disease.
There were 8,187 AIDS/deaths (1,852 deaths, 6,283 AIDS, 52
AIDS/death on the same date) during 327,003 person-years of
follow-up. The Kaplan-Meier probability of progression to AIDS/
death stratified by late presentation and late presentation with
advanced disease is shown in Figures 3A–3D. Late presenters or
late presenters with advanced disease within each region had a
steep increase in probability of new AIDS/death within the first 1
or 2 y following presentation, but followed a similar curve as those
who did present late after this period, with some differences
between regions (p,0.0001, test for interaction).
This finding is explored in Table 3. Late presentation was
associated with the highest rate of AIDS/death in the first year
after HIV diagnosis among persons from Southern Europe
(adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19–20.70)
and the lowest rate in Eastern Europe (aIRR 6.64; 95% CI 3.55–
12.43). In the second year after diagnosis, late presentation was
associated with a higher rate of AIDS/death among persons from
Southern, Central, and Northern Europe, but was similar in both
late and non-late presenters from Eastern Europe. Late presen-
tation was not associated with an increased rate of AIDS/death
after the initial 2 y, within any European region of care. Also
shown are the results for late presentation with advanced disease,
which showed very similar findings. Late presentation was
associated with an increased rate of AIDS/death in those
presenting with advanced disease beyond 2 y in Southern Europe
(aIRR 1.38; 95% CI 1.01–1.88), and only in the first year after
Table 1. Characteristics at HIV diagnosis of late presenters and late presenters with advanced disease: COHERE 2000–2011.
Characteristics Subcharacteristics All Late Presenters Late Presents with Advanced Disease
n Percent n Percent n Percent
All 84,524 100 45,488 53.8 28,081 33.2
HIV exposure group MSMs 32,761 38.8 14,317 43.7 7,924 24.2
Male heterosexual 16,875 20.0 11,158 66.1 7,723 45.8
Female heterosexual 20,131 23.8 11,479 57.0 6,788 33.7
Male IDU 4,142 4.9 2,393 57.8 1,651 39.9
Female IDU 1,413 1.7 718 50.8 453 32.1
Male other 6,312 7.5 3,678 58.3 2,435 38.6
Female other 2,890 3.4 1,745 60.4 1,107 38.3
European region of care South 7,796 9.2 4,447 57.0 2,873 36.9
Central 39,949 47.3 21,729 54.4 13,192 33.0
North 35,583 42.1 18,748 52.7 11,673 32.8
East 1,196 1.4 564 47.2 343 28.7
Region of origin Europe 31,370 37.1 16,163 51.5 10,394 33.1
Africa 11,833 14.0 7,708 65.1 4,770 40.3
Other 5,812 6.9 3,348 57.6 2,157 37.1
Unknown 35,509 42.0 18,269 51.5 10,760 30.3
Delayed entry into carea 2,720 7.9 1,408 7.4 767 6.6
Median IQR Median IQR Median IQR
Age Years 36 30–43 38 31–45 39 32–46
CD4 count /mm3 333 160–523 175 70–270 94 36–160
Baseline Month/year 5/05 10/02–11/07 2/05 8/02–8/07 11/04 6/02–6/07
Late presentation: diagnosed with HIV with a CD4 count below 350/mm3 or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis.
Late presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm3or an AIDS defining event, regardless of CD4 cell count, in the 6 mo
following HIV diagnosis.
aDelayed entry into care: $3 mo between HIV diagnosis and first clinic visit, in those patients where both dates were recorded (n= 34,561). Baseline was defined as the
earliest of HIV test, first study visit, or cohort enrolment. ‘‘Other’’ regions included Central/Southern America (n= 4,277) and Asia (n= 1,005). ‘‘Other’’ HIV male and
female transmission groups included 5,350 (84.8%) and 2,046 (70.8%) patients with unknown HIV-exposure group, respectively, likely to include a number of IDUs,
MSMs, and heterosexuals.
IQR, interquartile range.
doi:10.1371/journal.pmed.1001510.t001
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Figure 1. Changes over time in late presentation and CD4 count at HIV diagnosis: COHERE 2000–2011. Late presentation: diagnosed
with HIV with a CD4 count below 350/mm3 or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Late
presentation with advanced disease: diagnosed with HIV with a CD4 count below 200/mm3or an AIDS defining event, regardless of CD4 cell count, in
the 6 mo following HIV diagnosis.
doi:10.1371/journal.pmed.1001510.g001
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diagnosis for those from Eastern Europe (aIRR 6.98; 95% CI
4.22–11.56). Results were similar when excluding patients with
unknown or delayed entry into care (Table S4).
The definition of late presentation or presentation with
advanced disease required that a CD4 count was measured within
6 mo of diagnosis. Table S5 considers the odds of having missing
CD4 count data, which was consistently higher in Eastern Europe
compared to Southern Europe in all HIV-exposure groups. The
proportion of late presenters and late presenters with advanced
disease varied quite widely, especially in Eastern Europe, as shown
in sensitivity analyses in Table 4. Changing the requirement for
the CD4 count to be measured within 1 mo or 12 mo of diagnosis
did not greatly alter the proportion of late presenters or late
presenters with advanced disease, while assuming those without a
CD4 count were late presenters increased the proportion of late
presenters to 61.9% overall (63,467/102,532) and 73.8% in
Eastern Europe (1,781/2,413). Conversely, assuming that those
without a CD4 count and without AIDS were not late presenters
lowered the proportion of late presenters to 45.1% overall
(46,242/102,532) and to 26.0% in Eastern Europe (627/2,413).
Discussion
This study included almost 85,000 persons diagnosed with
HIV across Europe after 1 January 2000 and found over half
were late presenters and one-third presented with advanced
disease using the HIV in Europe definition [2]. The study
focused on regional differences within HIV exposure groups,
providing important information for health care providers and
for future testing initiatives. Overall, late presentation de-
creased, and especially in MSMs. However, late presentation
remains a significant issue across Europe and in all HIV
exposure groups. Late presentation increased in male IDUs and
female heterosexuals from Southern and IDUs in Eastern
Europe. Late presentation was associated with an increased rate
of AIDS/deaths, particularly in the first year after HIV
diagnosis, although this also varied across Europe. Earlier and
more widespread testing, timely referrals after testing positive, as
well as improved retention in care strategies are required to
further reduce the incidence of late presentation.
The prevalence of late presentation was similar to that reported
from other recent European studies [14–17], as is the decrease in
late presentation [18,19]. Our study is unique in its ability to
report continent-wide changes within HIV exposure groups over a
significant period of time. The decreases in late presentation are
likely associated with changes to provider initiated HIV testing
policies and the massive scale-up of antenatal screening for HIV
[20,21]. Factors associated with late presentation in this and
previous studies included non-MSMs HIV-exposure group
[1,5,14,16,17,22], older age [1,14,16–19,23], and non-European
origin [14,17,19,22,24]. Reasons for the increase in late presen-
tation among IDUs in Eastern Europe and heterosexual females
and male IDUs from Southern Europe may include suboptimal
health care offered to these populations, differences in character-
istics that we were unable to adjust for, such as socioeconomic
status, the pattern of the underlying epidemic, and appearance of
symptoms that may ultimately promote presentation for care
[25,26]. Not all persons recommended for testing undergo testing
for a variety of reasons, including stigmatisation, discrimination,
criminalisation laws, lack of knowledge, or perceived risk [12]. Not
testing inevitably leads to later presentation and initiation of ART,
despite the fact that an alarmingly high proportion of the late
presenters have been in contact with the health system in the years
preceding HIV diagnosis [19,27].
As reported by others, late presentation or presentation with
advanced disease was associated with a significantly increased
incidence of AIDS/deaths [28,29]. We found an increased
incidence of AIDS/death, particularly in the first year after HIV
diagnosis [6,18,30]. There was also significant regional variation,
with a 13-fold increased rate in persons in care in Southern
Europe and a 6-fold increased rate in Eastern Europe. There was a
small increased rate of AIDS/death associated with late presen-
tation in the second year after diagnosis, with the exception of
Eastern Europe, and no differences after this time. Morbidity and
mortality among HIV-positive individuals in Eastern Europe has
been reported to be particularly poor in EuroSIDA [31], the only
contributor to COHERE with data from Eastern Europe.
Unfortunately, COHERE does not have additional data on
factors such as whether individuals are current IDUs, on opiate
substitution therapy, or alcohol dependant, all of which may
contribute to clinical progression after HIV diagnosis and which
likely vary significantly across regions.
Collaborations such as the HIV in Europe initiative have helped
raise awareness of HIV testing, and developed an indicator disease
testing strategy, whereby all persons presenting for care for a
number of indicator diseases are routinely tested for HIV [27].
Despite this and other strategies, individuals continue to test late
for HIV with consequences in terms of a poor prognosis, an
increased risk of onward HIV transmission, increased costs to the
health system, and suboptimal benefits of ART [2,32]. Increasing
awareness of HIV risk factors, increased opportunities for testing,
reducing barriers to testing, and increasing the availability of
effective ART will help address ongoing HIV transmission across
Europe, and especially in Eastern Europe where the number of
newly diagnosed infections continues to be very high [33].
Persons were required to have a CD4 count measured within
6 mo of presentation to be included in analyses. If those with
missing CD4 counts were assumed late presenters, the proportion
of late presenters rose to 62% overall and 74% in Eastern Europe,
with 45% overall and 65% from Eastern Europe having advanced
disease. Accurate information on CD4 count at presentation is
essential for monitoring late presentation, a recent report
suggested 18 of 28 countries routinely monitored CD4 count at
presentation, and only 11 had information on at least 50% of
persons testing HIV positive [34]. Missing CD4 counts were
consistently more likely in persons from Eastern Europe (Table S4)
among all HIV exposure categories. Persons from Eastern Europe
were exclusively included from the EuroSIDA cohort (details at
www.cphiv.dk). Participating sites are typically centres of excel-
lence, likely not representative of all persons in the region [35].
Further, inclusion criteria include a pre-booked clinic outpatient
appointment, meaning persons have to survive long enough to be
recruited to EuroSIDA, which may have excluded a number of
late presenters. Persons from Eastern Europe are known to have a
poor prognosis [31], and CD4 count may be more likely to be
missing in those who die before a CD4 count is measured [36]. As
a result, we are likely underestimating the proportion of and
consequences of late presentation in this region.
Figure 2. (A–D) Changes in late presentation over calendar time; stratified by HIV exposure group: COHERE 2000–2011. (A) Southern
Europe. (B) Central Europe. (C) Northern Europe. (D) Eastern Europe. All models adjusted for age, delayed entry into care ($3 mo) after HIV diagnosis,
region of origin, European region of care, and HIV mode of infection. F, female; Het, heterosexual; M, male.
doi:10.1371/journal.pmed.1001510.g002
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Some limitations of the study should be noted. Date of HIV
infection was assumed to be the date of first clinic visit or
enrolment into the participating cohort. We performed sensitivity
analyses excluding patients where HIV-test date was not reported
to COHERE with highly consistent results (Tables S2 and S3).
Late presentation and delayed entry into care can be thought of as
two distinct issues with different risk factors, interventions, and
outcomes [1,19,37]. Late presentation reflects patients who are
unaware of their HIV infection and do not test until their CD4
count has declined, while delayed entry into care reflects persons
who are aware of their HIV status but chose not to seek care for
their HIV. Less than 10% of our patient population had delayed
entry into care, although this information was only available for a
minority of patients. We excluded cohorts including only
seroconverters from our analyses, because persons in these cohorts
are unlikely to be late presenters. However, inclusion of these
cohorts did not substantially alter our findings (Table S2). Local
regulations meant information on ethnic origin was not available
for over 40% of persons, and likely includes a significant number
of migrants who are known to present later for testing [32].
In summary, while late presentation has decreased over time
across Europe, it remains a significant issue across the European
continent with implications for both individuals and the public
health in most European regions. Late presentation was associated
with an increased rate of AIDS/death, particularly in the first year
after HIV diagnosis. It is important that earlier HIV testing
Figure 3. (A–D) Progression to new AIDS/death: role of late presentation or late presentation with advanced disease: COHERE
2000–2011. (A) Southern Europe. (B) Central Europe. (C) Northern Europe. (D) Eastern Europe. LP, diagnosed with HIV with a CD4 count below 350/
mm3 or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis. Presentation with advanced disease (AD):
diagnosed with HIV with a CD4 count below 200/mm3 or an AIDS defining event regardless of the CD4 count, in the 6 mo following HIV diagnosis.
doi:10.1371/journal.pmed.1001510.g003
Table 3. Number and percentage of AIDS/deaths and adjusted incidence rate ratios of AIDS/death after HIV diagnosis in COHERE
2000–2011; late presenters versus non late presenters stratified by European region of care and time since presentation.
European Region of Care Years since Diagnosis n (%) AIDS/ Univariate Multivariate
Deathsa IRR (95% CI) p-Value aIRR (95% CI) p-Value
Late presenters versus non late presenters
South ,1 376 (95.2) 15.83 (9.97–25.10) ,0.0001 13.02 (8.19–20.70) ,0.0001
Central ,1 2,228 (93.5) 12.87 (10.94–15.14) ,0.0001 11.24 (9.54–13.25) ,0.0001
North ,1 1,528 (91.9) 10.70 (8.96–12.75) ,0.0001 9.30 (7.79–11.11) ,0.0001
East ,1 75 (86.2) 7.55 (4.10–13.88) ,0.0001 6.64 (3.55–12.43) ,0.0001
South 1–2 56 (70.0) 1.93 (1.20–3.11) 0.0070 1.55 (0.94–2.53) 0.081
Central 1–2 374 (69.5) 2.03 (1.69–2.43) ,0.0001 1.78 (1.48–2.15) ,0.0001
North 1–2 280 (64.7) 1.72 (1.42–2.10) ,0.0001 1.57 (1.29–1.93) ,0.0001
East 1–2 16 (45.7) 1.02 (0.53–1.99) 0.95 0.94 (0.47–1.91) 0.87
South .2 112 (64.4) 1.47 (1.08–2.01) 0.015 1.21 (0.88–1.67) 0.24
Central .2 726 (55.7) 1.04 (0.94–1.16) 0.45 0.95 (0.85–1.06) 0.35
North .2 535 (52.5) 0.96 (0.84–1.08) 0.47 0.88 (0.78–1.00) 0.049
East .2 35 (45.5) 0.90 (0.57–1.41) 0.64 0.80 (0.50–1.29) 0.36
Advanced disease versus non-advanced disease
South ,1 356 (90.1) 17.13 (12.31–23.85) ,0.0001 14.63 (10.46–20.47) ,0.0001
Central ,1 2,069 (86.8) 14.96 (13.28–16.84) ,0.0001 13.27 (11.77–14.98) ,0.0001
North ,1 1,437 (86.4) 14.14 (12.29–16.27) ,0.0001 12.45 (10.80–14.37) ,0.0001
East ,1 64 (73.6) 7.85 (4.88–12.65) ,0.0001 6.98 (4.22–11.56) ,0.0001
South 1–2 48 (60.0) 2.89 (1.85–4.52) ,0.0001 2.31 (1.46–3.68) 0.0004
Central 1–2 243 (45.2) 1.88 (1.59–2.23) ,0.0001 1.62 (1.36–1.93) ,0.0001
North 1–2 194 (44.8) 1.80 (1.49–2.17) ,0.0001 1.61 (1.32–1.96) ,0.0001
East 1–2 9 (25.7) 0.99 (0.46–2.11) 0.97 0.87 (0.39–1.94) 0.73
South .2 86 (49.7) 1.72 (1.28–2.32) 0.0004 1.38 (1.01–1.88) 0.041
Central .2 463 (35.5) 1.17 (1.05–1.31) 0.0061 1.06 (0.94–1.19) 0.32
North .2 351 (34.4) 1.02 (0.90–1.17) 0.72 0.94 (0.82–1.07) 0.33
East .2 21 (27.3) 0.86 (0.52–1.41) 0.54 0.75 (0.44–1.29) 0.30
Adjusted additionally for age, region of origin, delayed entry into care ($3 mo between HIV diagnosis and first clinic visit), and HIV-exposure group. Late presentation:
presenting for care with a CD4 count below 350/mm3 or presenting with an AIDS defining event regardless of the CD4 count, in the 6 mo following presentation.
Advanced disease: presenting for care with a CD4 count below 200/mm3or presenting with an AIDS defining event, regardless of CD4 cell count, in the 6 mo following
presentation.
aFigures are n (%) of clinical events (AIDS/deaths) in late presenters or late presenters with advanced disease.
doi:10.1371/journal.pmed.1001510.t003
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strategies are targeted to all populations at risk both within the
health care system and in community based programs, to ensure
timely referrals after testing positive, improved retention in care
strategies, and optimal clinical management and initiation of ART
in those testing HIV positive.
Supporting Information
Table S1 Summary of patients included and excluded
from the COHERE analysis of late presentation across
Europe: COHERE 2000–2011. *Persons were also excluded if
gender or HIV diagnosis was missing, if aged ,16, or if there was
evidence of an earlier HIV diagnosis (CD4 count, AIDS diagnosis,
or starting ART) more than 1 mo prior to the date of first clinic
visit. +Additionally excluded patients from Argentinean centres.
(DOCX)
Table S2 Adjusted odds of late presentation among
persons with known first clinic visit and without delayed
entry into care and including seroconverter cohorts
contributing to COHERE: COHERE 2000–2011.
(DOCX)
Table S3 Percentage of late presenters and adjusted
odds* of late presentation associated with later calendar
years of HIV diagnosis: a comparison across regions
and HIV exposure group. *Adjusted additionally for age,
region of origin, and delayed entry into care ($3 mo between HIV
diagnosis and first clinic visit). Late presentation: diagnosed with
HIV with a CD4 count below 350/mm3or an AIDS defining
event, regardless of CD4 cell count, in the 6 mo following HIV
diagnosis. F, female; Het, heterosexual; M, male.
(DOCX)
Table S4 Number and percentage of AIDS/deaths and
adjusted* incidence rate ratios of AIDS/death after HIV
diagnosis in COHERE 2000–2011: late presenters versus
non late presenters and late presentation with advanced
disease versus non-advanced disease stratified by
European region of care and time since presentation;
excluding persons with delayed entry into care or
unknown first visit date (n=31,733). Late presentation:
presenting for care with a CD4 count below 350/mm3 or
presenting with an AIDS defining event regardless of the CD4
count, in the 6 mo following presentation. Advanced disease:
presenting for care with a CD4 count below 200/mm3or
presenting with an AIDS defining event, regardless of CD4 cell
count, in the 6 mo following presentation. ‘Figures are n (%) of
clinical events (AIDS/deaths) in late presenters or late presenters
with advanced disease. *Adjusted additionally for age, region of
origin, and delayed entry into care ($3 mo between HIV
diagnosis and first clinic visit). + Persons from Northern Europe
were also excluded as the majority of persons from Northern
Europe had delayed entry into care or unknown first visit date.
(DOCX)
Table S5 Odds of missing CD4 count in the 6 mo
following HIV diagnosis stratified by HIV exposure
group: COHERE 2000–2011. Male and females belonging to
the ‘‘Other’’ HIV exposure group were combined into a single
category.
(DOCX)
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Editors’ Summary
Background. Every year about 2.5 million people become
newly infected with HIV, the virus that causes AIDS. HIV can
be transmitted through unprotected sex with an infected
partner, from an HIV-positive mother to her unborn baby, or
through injection of drugs. Most people do not become ill
immediately after infection with HIV although some develop
a short influenza-like illness. The next stage of the HIV
infection, which may last up to 10 years, also has no major
symptoms but, during this stage, HIV slowly destroys
immune system cells, including CD4 cells, a type of
lymphocyte. Eventually, when the immune system is unable
to fight off infections by other disease-causing organisms,
HIV-positive people develop AIDS-defining conditions—
unusual viral, bacterial, and fungal infections and unusual
tumors. Progression to AIDS occurs when any severe AIDS-
defining condition is diagnosed, when the CD4 count in the
blood falls below 200 cells/mm3, or when CD4 cells account
for fewer than 15% of lymphocytes.
Why Was This Study Done? People need to know they
are HIV positive as soon as possible after they become
infected because antiretroviral therapy, which controls but
does not cure HIV infection, works best if it is initiated when
people still have a relatively high CD4 count. Early diagnosis
also reduces the risk of onward HIV transmission. However,
40%–60% of HIV-positive individuals in developed countries
are not diagnosed until they have a low CD4 count or an
AIDS-defining illness. Reasons for such late presentation
include fear of discrimination or stigmatization, limited
knowledge about HIV risk factors, testing, and treatment
together with missed opportunities to offer an HIV test.
Policy makers involved in national and international HIV
control programs need detailed information about patterns
of late presentation before they can make informed
decisions about how to reduce this problem. In this study,
therefore, the researchers use data collected by the
Collaboration of Observational HIV Epidemiological Research
in Europe (COHERE) to analyze trends in late presentation
over time across Europe and in different groups of people at
risk of HIV infection and to investigate the clinical conse-
quences of late presentation.
What Did the Researchers Do and Find? The researchers
analyzed data collected from 84,524 individuals participating
in more than 20 observational studies that were undertaken
in 35 European countries and that investigated outcomes
among HIV-positive people. Nearly 54% of the participants
were late presenters—individuals who had a CD4 count of
less than 350 cells/mm3 or an AIDS-defining illness within 6
months of HIV diagnosis. Late presentation was highest
among heterosexual males, in Southern European countries,
and among people originating in Africa. Overall, late
presentation decreased from 57.3% in 2000 to 51.7% in
2010/11. However, whereas late presentation decreased over
time among men having sex with men in Central and
Northern Europe, for example, it increased over time among
female heterosexuals in Southern Europe. Finally, among the
8,000 individuals who developed a new AIDS-defining illness
or died during follow-up, compared to non-late presentation,
late presentation was associated with an increased incidence
of AIDS/death in all regions of Europe during the first and
second year after HIV diagnosis (but not in later years); the
largest increase in incidence (13-fold) occurred during the
first year after diagnosis in Southern Europe.
What Do These Findings Mean? These findings indicate
that, although late presentation with HIV infection has
decreased in recent years, it remains an important issue
across Europe and in all groups of people at risk of HIV
infection. They also show that individuals presenting late
have a worse clinical outlook, particularly in the first and
second year after diagnosis compared to non-late presenters.
Several aspects of the study design may affect the accuracy
and usefulness of these findings, however. For example,
some of the study participants recorded as late presenters
may have been people who were aware of their HIV status
but who chose not to seek care for HIV infection, or may
have been seen in the health care system prior to HIV
diagnosis without being offered an HIV test. Delayed entry
into care and late presentation are likely to have different risk
factors, a possibility that needs to be studied further. Despite
this and other study limitations, these findings nevertheless
suggest that HIV testing strategies that encourage early
testing in all populations at risk, that ensure timely referrals,
and that improve retention in care are required to further
reduce the incidence of late presentation with HIV infection
in Europe.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1001510.
N Information is available from the US National Institute of
Allergy and infectious diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS,
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including detailed
information on the stages of HIV infection and on HIV and
AIDS in Europe (in English and Spanish)
N The HIV in Europe Initiative has information about
strategies to improve earlier diagnosis and access to care
in Europe
N Information about COHERE, which was established in 2005
to conduct epidemiological research on the prognosis and
outcome of HIV-infected people from across Europe, is
available; more information on the consensus definition of
late presentation used in this study is available through the
HIV in Europe initiative
N Patient stories about living with HIV/AIDS are available
through Avert and through the nonprofit website
Healthtalkonline
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